Plenary Session
Plenary Session
Vinay Prasad, MD MPH
4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial
18 minutes Posted Jun 4, 2022 at 7:33 pm.
0:00
18:01
Download MP3
Show notes
Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint
No OS
Bad crossover
Lots to discuss here
I will be covering all the major ASCO papers on @PlenarySession
Subscribe to my substack https://vinayprasadmdmph.substack.com/